16 July 2025
Image Credits: Allerin
The pharmaceutical industry is facing difficulties in gaining the public's trust. The drug reactions often cause adverse effects to health and are not suitable for every individual. The advancement and development could help the pharma’s ship to sink. The current scenario is not in favor of pharmaceutical companies. The opioid epidemic, drug prices, and overdo marketing tactics are major problems. The advanced AI and pharmacogenetics are building the pharmaceutical industry’s reputation.
Pharmacogenetics has evolved over the decades. Pharmacogenetics is the study of genes to drug response. This makes prescriptions more accurate, effective, and safer. The drug response cannot be recognized by an individual gene. It is addressed by metabolic pathways, lifestyle factors, intricate interactions between various genetic markers, and environmental influences. The manual analysis of several variables generates personalized prescriptions which is more precise than human capabilities. Though the computational model does not cover the vast data.
Artificial Intelligence is a change to this situation. Pharmacogenetics startup ‘PGxAI’ is highlighting the advanced AI’s potential to strengthen this startup double then expected. The advanced AI platform can combine a vast dataset via genomics, epigenetics, microbiome/diet profiles, and transcriptomics. All these systems can be tested on different patient populations globally and are accepted to adapt to treat/address differences in drug metabolism. The impact of these systems is insightful. The studies have witnessed that around 98% of individuals have one genetic variant that might affect them in some way.
According to meta-analyses, the pharmacogenetics insights can minimize the scenario of adverse drug reactions by 30%. It’s not an improvement; it’s a direct intention to reduce a global leading cause of preventable death. The implementation has not yet been enforced, as pharmacogenetics real-world, large dataset is not able to provide AI training. With no AI system, an incentive is needed to collect data.
The main health systems, such as Massachusetts General Hospital, the Department of Veterans Affairs, the Mayo Clinic, and Mount Sinai, are gathering genomic data with clinical records. Million Health Discoveries program 2022 at Mount Sinai was launched in partnership with the Regeneron Genetics Center. The program will gather 1 million patients and merge their genetic data with the addressed electronic health records. The VA’s Million Veteran Program 2011 has exceeded 1 million patients, which is the world’s largest and diverse biobank. Mayo Clinic’s biobank has expanded its international reach via a partnership with the All of Us Research Program.
16 July 2025
15 July 2025
15 July 2025
15 July 2025